
    
      Subjects with intolerance to current regimen will receive Raltegravir 400 mg twice daily and
      Atazanavir 400 mg daily will be monitored for viralogical and immunological outcomes, changes
      in lipids, renal and hepatic safety and quality of life.
    
  